Imatinib is under clinical development by Aerami Therapeutics and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Imatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Imatinib overview

Imatinib (AER-901) is under development for the treatment of pulmonary arterial hypertension. It is administered through inhalation route. It acts by targeting Bcr-Abl tyrosine kinase, platelet derived growth factor receptor and mast/stem cell growth factor receptor kit.

Aerami Therapeutics overview

Aerami Therapeutics (Aerami) formerly Dance Biopharm Inc, is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company provides product pipeline such as Dance-501, a pocket-sized inhaler device and insulin container, among others. It has completed Phase II clinical trials and is in preparation for pivotal development. Aerami offers Dance-501 that being designed to control prandial blood sugar in adults with diabetes without the need for injections. The company develops liquid formulation of insulin based on the vibrating mesh micropump technology developed and commercialized by Aerogen. Aerami is headquartered in San Francisco, California, the US.

For a complete picture of Imatinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.